Apellis Pharmaceuticals Inc (NAS:APLS)
$ 28.075 -0.485 (-1.7%) Market Cap: 3.49 Bil Enterprise Value: 3.59 Bil PE Ratio: 0 PB Ratio: 12.94 GF Score: 42/100

Q3 2022 Apellis Pharmaceuticals Inc Earnings Call Transcript

Nov 07, 2022 / 09:30PM GMT
Release Date Price: $47.62 (-5.55%)
Operator

Hello, and thank you for standing by. Welcome to the Q3 2022 Apellis Pharmaceuticals Earnings Conference Call. (Operator Instructions). I would now like to hand the conference over to your speaker, Meredith Kaya, Senior Vice President of Investor Relations and Strategic Finance. Please go ahead.

Meredith Kaya
Apellis Pharmaceuticals, Inc. - SVP, IR & Strategic Finance

Good afternoon, and thank you for joining us to discuss Apellis' Third Quarter 2020 Financial Results. With me on the call are Co-Founder and Chief Executive Officer, Dr. Cedric Francois, Chief Commercial Officer, Adam Townsend, Chief Medical Officer, Dr. Federico Grossi; and Chief Financial Officer, Tim Sullivan. Before we begin, I would like to point out that we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors discussed in our SEC filings for additional detail. Now I'll turn the call over to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot